Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
Completed
Boehringer Ingelheim
Phase 2
2004-11-01
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled
Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)
Completed
Boehringer Ingelheim
Phase 4
2002-05-01
To compare the bronchodilator efficacy of ipratropium plus salbutamol (Combivent) with
salbutamol alone given every 20 minutes for three doses in asthmatic children with severe
acute exacerbation
Bronchodilators and Oxygen Kinetics With Exercise in Chronic Obstructive Pulmonary Disease (COPD) Patients
Completed
Queen's University
Phase 4
2006-03-01
Hypothesis: The reduction of dynamic hyperinflation and its negative effects on the
respiratory system following a bronchodilator could lead to an improvement of cardiac
function in terms of increased cardiac output. This may enhance oxygen delivery to the
exercising muscles in COPD patients. Bronchodilator administration may also have an indirect
effect on V'O2 kinetics via its action on cardiovascular and pulmonary variables.
Objectives:
1. To evaluate the effects of a bronchodilators on V'E , V'CO2 , and V'O2 kinetics in COPD
during constant work-rate cycle exercise, and to evaluate whether bronchodilators will
accelerate, indirectly, phase 2 kinetics (usually slower in COPD patients than normal
subjects) and shorten t for V'E, V'CO2 , and V'O2 and shorten half-times for HR and O2
pulse, thus showing an improvement of oxygen transport to the peripheral active muscles.
2. To determine the impact of a bronchodilator-induced reduction in dynamic hyperinflation,
and its effects on cardiovascular and pulmonary function, on exercise limitation in
COPD.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.